Thursday, November 13, 2014

REMINDER: UVM Cancer Center Retreat, Friday, Nov. 14

UVM Cancer Center Research Symposium: Call for Posters and RSVPs

Vermont Colorectal Cancer Summit November 15

Leunigs’ Event to Benefit Men’s Health and Cancer Efforts at the UVM Cancer Center

Brovember Efforts Underway at the UVM Cancer Center

Clinical Trials News

Publications and Announcements

Funding Opportunities- NEW LISTING THIS WEEK

Ongoing Events

Weekly Event Spotlight

Fall 2014 UVM Cancer Center Member Retreat

A reminder that the UVM Cancer Center member retreat is on Friday, November 14 from 12-5 PM. The event will take place in the Waterman building’s Memorial Lounge and
**Vermont Colorectal Cancer Summit**

Saturday, Nov. 15, 2014
10 AM to 2 PM
Davis Auditorium
UVM Medical Center

Contact Justin Pentenrieder for more information.

---

**Save the Date**

**November 2014**

*Lung and Pancreatic Cancer Awareness Month*

14 **UVM Cancer Center Member Retreat**; for UVM Cancer Center members and staff only; 12-5 PM, Memorial Lounge, Waterman Building; for more information please contact Charles Brooks.

15 **UVM Athletics' Rally Against Cancer Event**: UVM Swim Team meet, 2 PM UVM Pool.

15 **ACS/VTAAC/UVM Cancer Center "Vermont Colorectal Cancer Summit"**: Davis Auditorium, UVM Medical Center, 10-2 PM; contact Justin Pentenrieder@cancer.org.

16 **Leunigs' Bistro Event to Benefit the UVM Cancer Center. All-day proceeds from sales to benefit men's cancer research at the UVM**

---

**2014 University of Vermont Cancer Center Clinical and Translational Research Symposium: Nov. 21**

**Deadlines Approaching!**

RSVP today for the upcoming UVM Cancer Center Clinical and Translational Symposium!

Submit a poster (representing any cancer-related research here at UVM) for a day-long exhibition and competition. Cash prizes in each of the Pre/Post-Doc and Faculty/Staff categories will be awarded. Poster abstracts must be received by Friday, November 14.

Questions? Please contact Sarah Keblin.
18 UVM Cancer Center Grand Rounds; Chronic Opioid Protocol presentation and practical training, featuring Carlos Pino, MD; Reardon Classroom (MedEd 300), 8-9 AM.

18 Norris Cotton Cancer Center Grand Rounds via live webcast: "Cancer and Sexuality -- A survivorship Issue"; 12-1 PM; click here to view live.

19 Pathology Grand Rounds: Advancing and Securing Our Future in the Evolving Pathology Political Landscape, Gene Herbek, MD, FACP, President of the College of American Pathologists; Davis Auditorium, 1-2 PM.

18-21 AACR International Symposium on Molecular Targets and Cancer Therapeutics; Barcelona, Spain.

21 UVM Cancer Center Clinical and Translational Research Symposium; Molecular and Behavioral Cancer Epidemiology; Davis Auditorium, UVM Medical Center, 8:00-4:30. RSVP to Charles Brooks.

December 2014

1-4 AACR Special Conference on Tumor Immunology and Immunotherapy: A New Chapter; Orlando, FL.

2 UVM Cancer Center Special Lecture: Nanoknife, featuring Paul Oberstein, MD, New York Presbyterian Hospital, Columbian University Medical Center; Reardon Classroom (Med

ACS and VTAAC to Lead Vermont Colorectal Cancer Summit at the UVM Cancer Center

On Saturday, November 15 from 10 AM to 2 PM at the University of Vermont Medical Center's Davis Auditorium, the American Cancer Society and Vermonters Taking Action Against Cancer (VTAAC), with support from the University of Vermont Cancer Center, will host a Vermont Colorectal Cancer Summit. The event is aimed at reducing the burden of colon cancer in Vermont. The free, four-hour event will cover the latest developments in treatment and share proven ways to improve screening rates. Expert panelists will walk attendees through the screening process and share best practices as well as new tools.

Primary care physicians, nurses, physician assistants, nurse practitioners and other medical professionals with an interest in cancer prevention, screening, and treatment are encouraged to attend.

Guest speakers include experts from the University of
Vermont Cancer Center, the American Cancer Society, Blue Cross Blue Shield of Vermont Vermonters Taking Action Against Cancer and the Vermont Department of Health, as well as cancer survivors.

For registration information, please contact Justin Pentenrider at the American Cancer Society.

---

**Leunigs' Bistro to Host November 16 Fundraiser for Men's Cancer Research and Education at the UVM Cancer Center**

In follow-up to their month-long efforts to raise funds and awareness for the High Risk Breast Program at the University of Vermont Cancer Center, Leunigs' Bistro, on Church Street in Burlington, will be hosting an all-day fundraiser on Sunday, November 16th. Proceeds from sales throughout the day will benefit men's health and cancer research and education efforts at the UVM Cancer Center.

Mark you calendar and join other UVM Cancer Center members, staff and faculty for brunch, lunch or dinner!

For more information, please contact Manon O'Connor.

---

**Return of the MO--to Benefit the UVM Cancer Center!**

November is under way and so is facial hair growth for a fantastic group of providers, staff and students at the University of Vermont Cancer Center! They have launched a local effort to build awareness and funding for men's cancer research and education efforts happening here at the UVM Cancer Center. They've dubbed their effort Brovember, and invite others in the community to join in the fun. You don't have to grow a "Mo" to participate. You can donate to a "bro" growing a "Mo" or make a general donation to the cause. To learn more click here, or, contact Sr. Director of Development Manon O'Connor.
Clinical Trials News

Three New PARP Inhibitor Trials in Breast and Ovarian Cancer Patients with BRCA1 or BRCA2 Mutations

There are currently three PARP inhibitor trials available at the University of Vermont Cancer Center for individuals with BRCA mutations. Two are for breast cancer patients, and one for ovarian cancer patients. The first breast trial is comparing the efficacy and tolerability of Olaparib (the PARP inhibitor) to the physician's choice between three different regimens (capecitabine, vinorelbine, or eribulin) for metastatic BRCA1/2 mutated patients. Potential participants should have received prior treatment with an anthracycline and taxane in either an adjuvant or metastatic setting and must be HER2 negative.

The second breast trial is a double-blind, placebo-controlled trial comparing the efficacy and tolerability of carboplatin and paclitaxel plus veliparib (the PARP inhibitor)/placebo for locally advanced and unresectable or metastatic BRCA1/2 mutated patients. Potential participants should not have received treatment with a taxane previously and must be HER2 negative.

The ovarian trial is a double-blind placebo-controlled trial
looking at Olaparib monotherapy as a maintenance regimen in patients with ovarian cancer and BRCA mutations following first-line, platinum-based chemotherapy. These patients must have completed first line platinum therapy with clinical complete response or partial response and have no clinical evidence of disease progression on the post treatment scan nor a rise in CA-125.

All of these trials can be found on the UVM Cancer Center website which contains contact information for each of the three studies.

For more information about the breast trials contact Hannah Eldred; for the ovarian trial contact Jen Holmes.

Click here to view a list of UVM Cancer Center clinical trials.

Publications and Announcements
*Please send announcements and publication notices to Sarah Keblin for inclusion in the weekly eALERT and other promotional material*

Recent Publications by UVM Cancer Center Members:


Funding Opportunities
Green indicates NEW this week

- NCI Innovative Research in Cancer Nanotechnology (IRCN) (U01); deadline for submission *multiple
• **Damon Runyon Physician-Scientist Training Award**; four years of funding totaling $460,000 plus debt retirement up to $100,000; deadline for application is **Monday, December 1, 2014**.

• **2015 Kimmel Scholar and Translational Science Award**; $200K over two years for junior faculty research in cancer; application deadline is **December 3, 2014**.

• **UVM Reach Grants**; providing seed funding to promote innovative research, scholarship and creative arts at UVM; deadline for submission is **December 5, 2014**.

• **Landon Foundation-AACR Innovator Award for Research in Tumor Microenvironment**; 2-year, $135,000 junior faculty grant for AACR members; application deadline is **December 9, 2014, noon**.

• **NIH Director’s Early Independence Awards (DP5)**; limited competition award--UVM may put forth two applicants and is seeking nominations for investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period; **please send nominees' CV and a brief statement speaking to the strengths of the nominee to UVM's Hilda Alajajian by November 17, 2014** (letters of intent for invited nominees will be due on December 30, 2014, with full application due January 30, 2015).

---

**UVM Cancer Center Internal Funding/Grants Available**

[Click Here](#)
VCC Leadership:
Gary S. Stein, PhD, Co-Director
Claire F. Verschraegen, MD, Co-Director
Kate Webster, Administrative Director
Sarah Keblin, Communications Manager